{"id":183277,"date":"2026-05-18T01:01:59","date_gmt":"2026-05-18T05:01:59","guid":{"rendered":"https:\/\/alphastreet.com\/india\/krishna-institute-of-medical-sciences-limited-kims-q4-2026-earnings-call-transcript\/"},"modified":"2026-05-18T01:05:12","modified_gmt":"2026-05-18T05:05:12","slug":"krishna-institute-of-medical-sciences-limited-kims-q4-2026-earnings-call-transcript","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/krishna-institute-of-medical-sciences-limited-kims-q4-2026-earnings-call-transcript\/","title":{"rendered":"Krishna Institute of Medical Sciences Limited (KIMS) Q4 2026 Earnings Call Transcript"},"content":{"rendered":"

Note:<\/strong> This is a preliminary transcript and may contain inaccuracies. It will be updated with a final, fully-reviewed version soon.<\/em><\/p>\n

Krishna Institute of Medical Sciences Limited (NSE: KIMS) Q4 2026 Earnings Call dated May. 18, 2026<\/span><\/strong><\/p>\n

Corporate Participants:<\/h2>\n

Bhaskara Rao Bollineni<\/strong> \u2014 Founder and Managing Director<\/em><\/p>\n

Sachin Ashok Salvi<\/strong> \u2014 Chief Financial Officer<\/em><\/p>\n

Abhinay Bollineni<\/strong> \u2014 Chief Executive Officer<\/em><\/p>\n

Analysts:<\/h2>\n

Rahul Jiwani<\/strong> \u2014 Analyst<\/em><\/p>\n

Unidentified Participant<\/strong><\/p>\n

Alankar Garude<\/strong> \u2014 Analyst<\/em><\/p>\n

Damayanti Kerai<\/strong> \u2014 Analyst<\/em><\/p>\n

Karan Vora<\/strong> \u2014 Analyst<\/em><\/p>\n

Presentation:<\/h2>\n

Operator<\/strong><\/p>\n

Ladies and gentlemen, good day and welcome to Kim’s Hospital Q4FY26 earnings conference call hosted by IIFL Capital. As a reminder, all participant lines will be in the listen only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance in the conference call, please signal an operator by pressing Star then zero on your touchstone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Rahul Chiwani.<\/p>\n

Thank you. And over to you, Mr. Jiwani.<\/p>\n

Rahul Jiwani<\/strong> \u2014 Analyst<\/em><\/p>\n

Hi. Good morning everyone. This is Rahul from IFL Capital. I welcome you all to the fourth quarter earnings conference call of Kim’s Hospitals being hosted by IFL from Kim’s. We have with us today Dr. Bhaskar Rao Bolineni, founder and managing director Dr. Abhinay Bolineni, executive director and CEO and Mr. Sachin Salvi, CFO. Over to you sir for your opening comments.<\/p>\n

Bhaskara Rao Bollineni<\/strong> \u2014 Founder and Managing Director<\/em><\/p>\n

Good morning. Hearty welcome to all of you. The closure of financial year 2026 coincided with the beginning of the ongoing Gulf War with ramifications across many countries in the world including India. The recent appeal by Prime Minister for austerity measures underlines the grim scenario. Let us heed the call of the Prime Minister and ensure optimum utilization of resources till normalcy is restored. Let us hope and pray that better census will prevail and war will soon come to an end. In the present, world war between any two countries is impacting many countries because of their interdependence.<\/p>\n

I am aware that all of you are eagerly awaiting our financial results. I am happy to announce that Kims registered a stable growth quarter four financial year 26 highlights total revenue of INR 1,084 crore. A growth of 35.3% on year on year and 8.1% on quarter on quarter basis. EBITDA of INR 216 crore. The growth of 6.8% on year on year and a 5.9% on quarter on quarter basis. EBITDA margin at 19.9% versus 25.3% in quarter four financial year 25 and 20.4% in quarter three financial year 26 batch at INR 33 crores in quarter four financial year 26 against INR 106 crore and INR 52 crore in quarter four financial year 25 and quarter three financial year 26 respectively.<\/p>\n

Financial year 26 highlights total revenue of INr 3,931 crore. A growth of 28.2% on year on year basis. EBITDA of INR 828 crore a growth of 1.6% on year on year basis. EBITDA margin of 21.1% versus 26.6% in financial year 25 PAT at INR 242 crores in financial year 26 against INR 415 crore in financial year 25. Consolidated earning per share for financial year 26 of INR 6 not 6.03 a decline of 37.2% on year on year Basis quarter four financial year financial highlights consolidated consolidated revenue from operations is INR10.75 crore a growth of 34.8% on year on year 7.7% on quarter on quarter basis.<\/p>\n

Consolidated EBITDA pre ind as is INR 131 crore a decline of 33.5% and 32.3% on year on year and quarter on quarter basis respectively. Operational Highlights Quarter 4 Financial Year 26 Average revenue per operating debt grew by 13.7% and 1.7% on year on year and quarter on quarter basis respectively. Average revenue per patient grew by 14% and 3.5% on year on year and a quarter on quarter basis respectively. IP volumes grew by 17.9% and 4% on year on year and quarter on quarter basis respectively.<\/p>\n

Volumes grew by 30.1% and 4.1% on year on year and quarter on quarter basis respectively. Financially at 26 operational highlights average revenue per operating bed grew by 14% on year on year basis. Average revenue per patient grew by 11.4% on year on year basis. IP and workee volumes grew by 15.4% and 25.4% respectively on year on year basis. Thus, the operational parameters demonstrated a consistent upward trend. It augurs well that new units at Bangalore, Thane, Kerala, Nasik and Setamdara Vizag contributed significantly to top line growth.<\/p>\n

The mature units maintained healthy growth pattern. Expansions necessarily involve heavy expenditure and it stains the profits in the initial phase. Likewise, the profit of the company for the year is impacted though growth remains stable. However, the new units also will turn the tide sooner than expected and the prospects are already visible. 2526 has been a year of expansions. We opened one more hospital in Hyderabad at Pompani, two in Guntur, two in Maharashtra at Thane and Sangli, two in Bangalore, Madhyapura and Electronic City and one in Kerala at Kollam.<\/p>\n

We also opened faculty centers at Hyderabad and Guntur. Expansion has no meaning without clinical excellence and excellence is incomplete without empathy. All these new units reflect above concepts of excellence and empathy and already started making great imprints in their respective zones. I am happy to state that we accomplished an important milestone of completing 10,000 plus successful brain tumor surgeries at Kim’s. An exclusive cancer block was recently inaugurated at Kim’s Hospital Mongol to meet the medical needs locally without patients running far and wide.<\/p>\n

We opened Kim’s Kadils, a mother and child unit at Nilore on 4th February 2026 International Cancer Day program was organized to promote awareness. Megastar Padma Vibhush and Sharanjeevi took part as chief guest making the International Locust Day Kim’s Hospital Sikinderabad organized a unique ramp walk featuring Locust warriors on 11 May attended by family members and healthcare professionals across the city. This happens to be the fifth such locust ramp walk initiative in Asia. Yesterday, that is the 7th of May was world hypertension Day.<\/p>\n

Hypertension, or elevated blood pressure is a common condition with the prevalence of 1 in 3 adult Indians. This condition is dangerous but silent and causes a huge disease burden in the forms of heart disease, brain stroke, renal failure, eye disease and peripheral vascular disease. The danger is more since it often produces no symptoms by itself until target organ damage is already established and so it is appropriately called silent killer. Large studies have shown that early detection and appropriate management can prevent the adverse effects of this disease.<\/p>\n

Early detection relies on screening programs across the populations and education to follow a healthy lifestyle. Thus, high blood pressure is the gateway for mental health. Many health issues and timely action will enable mitigate many problems. Considering the paramount significance, we gave a call to all our unit heads across the group to organize BP checkups in a massive scale of 1 lakh at random places like railway stations, bus stands, offices, etc. All the units spontaneously responded to the call in a resounding way despite the short notice and accomplished 2 lakhs 4000 numbers more than double our expectations due to vigorous campaigning.<\/p>\n

Besides the numbers, it succeeded in creating awareness on a wide scale. We strongly believe that prevention is better than cure and this step demonstrates our philosophy. Being a healthcare professional, I thought it fit to appraise you also but the ill effects of hypertension on this occasion. Finally, it is said that there is no happiness in medicine and there is no medicine like happiness. I thank you for continued support and trust. Thank you very much. We can open it.<\/p>\n

Operator<\/strong><\/p>\n

Shall we open the line for questions?<\/p>\n

Bhaskara Rao Bollineni<\/strong> \u2014 Founder and Managing Director<\/em><\/p>\n

Yes,<\/p>\n

Questions and Answers:<\/h2>\n

Operator<\/strong><\/p>\n

Thank you. We will now be beginning the question and answer session. Anyone who wishes to ask a question may press Star and one on your touchstone telephone. If you wish to remove yourself from the question queue, you May press star on 2 participants are requested to use handsets while asking a question. Ladies and gentlemen, we’ll wait for a moment while the question queue assembles. The first question comes from the line of Balamurli Krishna with Oman investment advisor. Please go ahead.<\/p>\n

Unidentified Participant<\/strong><\/p>\n

Hi, good morning sir. So my first question is regarding this edition changes in<\/p>\n

Operator<\/strong><\/p>\n

The presentation. Earlier we have a lot of variation in Andhra Pradesh which is not available now and also Telangana elevated. So is there any changes in plan? Sir and also timelines are not available. So how do we see this?<\/p>\n

Unidentified Participant<\/strong><\/p>\n

Yeah. Hi Balakrishna, this is Vijay here. So the change is only because of, you know we are coming up planning for QIP in a month or two. So. So what has happened is, you know to align with the councils, you know, the prospectus and everything. We have given this time only the information which is being, you know, informed to exchanges and all. But the earlier plan is, you know, is on track. And we will update the presentation next quarter.<\/p>\n

Operator<\/strong><\/p>\n

Okay, sure. Thank you. So in second day and this in 2025, 26 opened a lot of new assets. So what is the contribution of those largest assets in the current revenue and what is the ebitda? Mostly they are in EBITDA negative. So what could be the approximate percentage of ebitda?<\/p>\n

Unidentified Participant<\/strong><\/p>\n

So for quarter on quarter basics, if you see the mature unit for us remains in a steady position of a bit of, you know, 30% approximately. And new units which are, you know recently started for Karnataka specifically the place hospital there is a drag, initial drag, you know, that is only the, you know, taking away the ebitda.<\/p>\n

Sachin Ashok Salvi<\/strong><\/p>\n

So this is Sachin, the numbers if you’re asking around 1085 crore. The matured units in this quarter has contributed almost 862 crores of revenue. And the balance revenue of about 224 crore is from the newer units. Newer units we mean the units which are in operations for less than one year as on the date of financial statements. Whereas the EBITDA which we have reported almost 216 crore in this quarter. Out of that 250 odd crore is from the matured units. So to say that almost 28.5% or 29% of EBITDA margin from matured unit we continue to maintain as far as the newer units for the current quarter the EBITDA region is to the extent at about 32 crores.<\/p>\n

So this is roughly, this is accurately in the terms of numbers for the current quarters.<\/p>\n

Operator<\/strong><\/p>\n

Yeah, thanks Thanks a lot for this explanation. So when do you think lastly and when do you think that we can go to previously better numbers as these assets make sure and we can get those numbers maybe down the line one or one year or two years as we are expanding rapidly every year. So the EBITDA margins will be will settle at this range for the next three, four years.<\/p>\n

Sachin Ashok Salvi<\/strong><\/p>\n

Yes, please go ahead Dr. Abhinav.<\/p>\n

Operator<\/strong><\/p>\n

The better way to look at it is on a cluster, on cluster basis, every cluster. We are now disclosing the EBITDA margins at each cluster. So because we’re adding so much bed capacity in different clusters, there will be some depletion in EBITDA numbers. But as long as we’re able to grow that on a quarter on quarter basis, that’s the direction we should look at. That’s the guidance that we’d like to.<\/p>\n

Sachin Ashok Salvi<\/strong><\/p>\n

That’s all. Thanks a lot.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. Next question comes from the line of Aman Koel from IFA Capital And a reminder also to press star and one to ask a question. Please go back.<\/p>\n

Unidentified Participant<\/strong><\/p>\n

Yeah. Thank you sir. Thank you for the opportunity. So my question is related to the new units loss trajectory. Can you throw some colors on the the quarter on quarter losses on Nastik, Thane and newer Karnataka units.<\/p>\n

Operator<\/strong><\/p>\n

So Nasik for Q4 is around 1 crore loss. Thane is around 5 crore loss for Q4 and the rest of the losses are from Karnataka. I think it’s the losses in Maharashtra have narrowed down to just 6,7 crores now from both the new entities. Karnataka because Pest just got commissioned in the month of Jan there are some losses maybe by. Sorry, in December Pest got commissioned. Now that the ramp up is happening in Pest maybe towards the end of the year the losses from Pest also should narrow down. As far as Mahadevuram is concerned the losses are in the similar range of Thane which again will narrow down as soon as we get more and more insurance types.<\/p>\n

Unidentified Participant<\/strong><\/p>\n

Yeah. Thank you. Thank you sir. My next question is a little the Karnataka geography since we are new to the region and there are lots of bigger hospital chain like Apollo Amanibal in there. So how do you see the market as compared to the core cluster like Telangana and Andhra?<\/p>\n

Operator<\/strong><\/p>\n

Obviously it’s a new market but we are very happy with the way the ramp up has happened at Mahadevuram. Now it’s eight months old, eight, nine months old. We are doing an average of 17 crores a month based on Q4 number and we have very clear visibility of how it will go to 25, 30 crores over the next 12 months. So we don’t see any difference in how the ramp up would have happened in a city like Hyderabad or in Bangalore. Just that the timing for both the hospitals there was a gap and because of its the losses expanded and test we took a little longer for commission and the only difficulty of late is the insurance impairment.<\/p>\n

Once that gets solved, I think the growth trajectory is we’re pretty confident in all the hospitals that we commission.<\/p>\n

Sachin Ashok Salvi<\/strong><\/p>\n

Thank you sir. I will join that.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. A reminder to all the participants that you may press Star and one to ask a question. Next question comes from the line of Nancy Yagav Aleko, please go ahead.<\/p>\n

Abhinay Bollineni<\/strong><\/p>\n

Hi sir, thanks for the opportunity again. I also have a question on the new units to be able to calculate margins, would it be possible for you to tell the revenues and the EBITDA for Q4 for Mahadev E City and Thane. Is close to 17 crores per month. So does it come to around 51 crores?<\/p>\n

Operator<\/strong><\/p>\n

No. Madhyapura in Q4 is 49 crores. Is 17 crores. Thane is 47 crores.<\/p>\n

Abhinay Bollineni<\/strong><\/p>\n

Okay. And sir, could you also tell the losses individually for Mahadeshpur and Electronic City<\/p>\n

Operator<\/strong><\/p>\n

Is 14. Electronic City is 25, Tane is 5 and Nastic is 1.<\/p>\n

Abhinay Bollineni<\/strong><\/p>\n

Okay. And sir, Electronic City is 17 crores in revenue. Sorry, I’m not sure if I got that correctly.<\/p>\n

Operator<\/strong><\/p>\n

Yeah, for the quarter.<\/p>\n

Abhinay Bollineni<\/strong><\/p>\n

Okay, sure. Thank you. That’s all I wanted.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. Next question comes from the line of Alankar Garude with Kotak Institutional Equities. Please go ahead.<\/p>\n

Alankar Garude<\/strong><\/p>\n

Hi, good morning everyone. Sir, in the third quarter call you had mentioned that debt has peaked out and in the absence of any new expansion plans, debt should trend lower. Now then within a month you announced the qip. Can you help us understand the reasons behind the planned 1500 crore QIP? I mean does it mean that you have zeroed in on any new expansion plans?<\/p>\n

Sachin Ashok Salvi<\/strong><\/p>\n

Expansion plans? We’re still exploring.<\/p>\n

Operator<\/strong><\/p>\n

That’s part of the strategy. But the idea is now that the debt has reached its peak close to 3000 plus crores. The idea is we retire some debt and use the cash flow to do more green projects which anyways will take three to four years before they get commissioned. So there are one two small acquisition opportunities that can potentially come up over the next two quarters. But they’re not significantly big. They’re around 400, 500 beds both put together. But the idea is to retire a large amount of this will go to retired debt and use the cash flow to fund greenfield Expansion which will anyways take three to five years before they get commissioned.<\/p>\n

Alankar Garude<\/strong><\/p>\n

Which are these markets you are talking about for both the organic expansion as well as the acquisitions?<\/p>\n

Operator<\/strong><\/p>\n

All of them are in our core markets, Karnataka, Kerala, Andhra, Telangana mostly in these four months.<\/p>\n

Alankar Garude<\/strong><\/p>\n

Okay, so basically you will be retiring debt and then eventually will be pursuing the greenfield given that the cash flow requirement for the greenfield will be more back ended. Retiring debt is something which is possible with the qip. Is that the way to understand this? Okay,<\/p>\n

Damayanti Kerai<\/strong><\/p>\n

Thanks.<\/p>\n

Alankar Garude<\/strong><\/p>\n

Okay, fair enough. The second question is qualitatively, particularly on the insurance empanelment. Can you update us on the progress of the four new relatively new hospitals, Nasik, Thania and the two Bangalore one and vis a vis your initial expectations. If you can just highlight how each of these units have performed. Thank you.<\/p>\n

Operator<\/strong><\/p>\n

So from A I think what we underestimated is the time it takes to now get insurance impairments vis a vis how it was before. That has caused some delay in ramp up. But otherwise overall we are very happy with all the four hospitals. The way we’ve been able to get clinical talent. Had we got impairments like we could have in the past, the ramp up would have significantly been better than what it is today. In spite of which we are pretty happy with the trajectory of the revenue growth in most of these hospitals as far as imperilments are concerned.<\/p>\n

Narsic we still yet to get star, Medi Assist and gpsa. Patane we finally got GPSA and Medi Assist and STAR are almost through. That completes at least 70% of the volume of insurance but we’re yet to get the impairment. But at least the negotiations are more or less through. As far as Bangalore it will take three four more months before we are able to get the impairments.<\/p>\n

Alankar Garude<\/strong><\/p>\n

Just one quick follow up there. You mentioned about delays in the insurance empanelment. I mean was it more specific to FY26 and the standoff which happened with insurance providers for the industry or this is something which we should expect, I mean to continue going forward?<\/p>\n

Operator<\/strong><\/p>\n

I think there is a new council GIC which also got introduced in the same financial year and because of that there has led to a lot of confusion as to who empanels hospitals. Would GIC do it? Would companies do it directly? So that confusion also led to a significant delay in impaneling hospitals. I think eventually we’ll have to figure out a way to ease this and ensure that once the hospital is commissioned within six months, nine months, we’re able to get impanelments done<\/p>\n

Alankar Garude<\/strong><\/p>\n

Got it. That’s very helpful. Thank you very much.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. Next question comes from the line of Akshay Thakur with Helios Capital. Please go ahead.<\/p>\n

Sachin Ashok Salvi<\/strong><\/p>\n

Hi sir. Very good morning and thanks for taking my question. Sir, my question is related to capital raise. I wanted to know your strategic evaluation on. Let’s divide it in two parts. Say for example one would be taking it from the market. It could be debt or it could be QIP or any other source. Second would be, you know, doctors participation model that which we used to have earlier. So can you what is the strategic evaluation point between these two to raise capital from these two sources.<\/p>\n

Operator<\/strong><\/p>\n

So right now we have a debt of almost 3000 plus crores. We want to use this capital raise from the QIP to retire it. And most of the projects that we do at a project level we put in an equity of 40% of the project cost. 60, 65% is debt. Now Dr. Participation is usually a very very small amount. It tans amounts to only 2, 3 to 5% at best.<\/p>\n

Sachin Ashok Salvi<\/strong><\/p>\n

Okay, got it. So any like in current expansion plans do you evaluate this as well? This mod doctor participation model is<\/p>\n

Operator<\/strong><\/p>\n

Always, is always open. So doctors are always open to invest as and when they feel like.<\/p>\n

Sachin Ashok Salvi<\/strong><\/p>\n

Okay, got it sir. That. That was my only question. Thank you.<\/p>\n

Alankar Garude<\/strong><\/p>\n

Thank you.<\/p>\n

Operator<\/strong><\/p>\n

Next question comes from the line of Karan Bora with Goldman Sachs. Please go ahead.<\/p>\n

Karan Vora<\/strong><\/p>\n

Thank you for taking my question. So the first question is with respect to the Kondapur expansion. So I see that we’ve kind of increased the number of beds. So. So just any thoughts on the kind of capex we are planning and what are the timelines? When should these beds come online and if they will come in phases which is what we understand then like, like what will be the phase 1, 2, 3. What will be the timelines and the capex for it.<\/p>\n

Operator<\/strong><\/p>\n

So we will shift into the new Kundapur facilities starting in the first week of June. So the new hospital will have 800 beds in total. The old hospital, we will completely shut it down. We will transition over a period of one month. But we may continue to run the old facility for two, three months even after we transition and then we’ll shut it down. So the new hospital will have 800 beds of which in phase one because we’re already at an occupancy of 200 beds and we need headroom for growth we will commission at least 400 to 500 beds in phase one.<\/p>\n

The remaining 300 beds we will commission as and when the occupancy Increases.<\/p>\n

Karan Vora<\/strong><\/p>\n

Got it. And capex we’ve incurred for the whole project.<\/p>\n

Operator<\/strong><\/p>\n

Yeah. Except for I would say around 50 to 75 crores which we will incur. Not the FY27 but in FY28 and beyond which is to complete two additional floors which we don’t require at this point in time.<\/p>\n

Karan Vora<\/strong><\/p>\n

Sorry. 50 to 75. Sorry. 50 to 70 crores.<\/p>\n

Operator<\/strong><\/p>\n

50 to 75 crores. Or we don’t need it for the FY27. We may need it in FY28 or 29 based on how the ramp up happens.<\/p>\n

Karan Vora<\/strong><\/p>\n

Okay. Okay, got it. Got it. The second question is with respect to the Andhra Pradesh and Bangalore R pops. So Bangalore R pops, I see it looks like have risen like significantly Even the full year number shows like some 85,000 on the deck if I’m not wrong. So what has happened? And is this the new base or it’s just a one off where the mix was like just too good. And you go back to the 70s number which was originally envisaged. And similarly for Andhra Pradesh, what is the right run rate is 28,000 plus the new run rate or 24 to 26,000 is the one which we should think as normal run rate.<\/p>\n

Operator<\/strong><\/p>\n

As far as Bangalore is concerned, 75,000 is a heavy number to assume. If you actually look at Q3, Q4 and full year, the ALOS keeps changing. As the ALOS keeps changing, the R corp keeps moving up and down. But you should fairly assume for all models we should assume 75,000 as a base and work on it. It will take time before the hospital settles down because a lot of new programs are getting added, transplants are happening on an equity aggressive way. So but for modeling purpose we should just assume 75,000.<\/p>\n

Karan Vora<\/strong><\/p>\n

Got it. And Andra pops<\/p>\n

Operator<\/strong><\/p>\n

Likewise. And also that 26,000, 27,000 in Q3 and Q4 also remains the same.<\/p>\n

Karan Vora<\/strong><\/p>\n

Okay, got it. So that’s the base. That’s the normal base. Okay, Correct. And just a quick last question. So Maharashtra, what was the Q4 occupancy? Because the implied number when I do it like it looks fairly high at like 60, 65% plus to arrive at that 52.1% number for the full year. Right. So, so is that a fair number or is there some error like<\/p>\n

Operator<\/strong><\/p>\n

60.5% occupancy for Q4.<\/p>\n

Karan Vora<\/strong><\/p>\n

Okay, okay, got it. And is that again like is that sustainable? Because it looks like a massive ramp up from 35% in Q1 to like 60% plus in Q4. So should we assume like a 60% or that kind of a number as the new base for Maharashtra occupancy.<\/p>\n

Operator<\/strong><\/p>\n

Okay,<\/p>\n

Karan Vora<\/strong><\/p>\n

Okay, got it. That’s. That’s helpful. Yeah. Thank you.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. Next question comes from the line of Abhishek Gupta with this capital. Please go ahead. Mr. Gupta, please go ahead with your question.<\/p>\n

Sachin Ashok Salvi<\/strong><\/p>\n

Hey, good morning. Thanks for taking the question. In Telangana and Hyderabad particularly which we do know as a more mature market, we saw it volumes increase by 2% whereas the overall revenue mix was increasing by 12% plus. Right. So most of it is value driven. How do we sort of see this going forward in the next year or two?<\/p>\n

Operator<\/strong><\/p>\n

Sorry, Abhishek again<\/p>\n

Sachin Ashok Salvi<\/strong><\/p>\n

Saying on a<\/p>\n

Operator<\/strong><\/p>\n

Year on year basis.<\/p>\n

Sachin Ashok Salvi<\/strong><\/p>\n

Yeah, yeah. So in Hyderabad which is a mature market for the larger healthcare space, we saw the IP volumes increased by 2%. Right. And the rest of it was driven by value. So how do we sort of see this number going forward in the next year or two?<\/p>\n

Operator<\/strong><\/p>\n

I think because as a cluster Telangana now we have added Kompali which is. Which got commissioned two months ago. The new Kondapuru commission now and in, in the next 18 months expansion in Kim Sikh in the bed will happen. So once these expansion happen the growth will be largely volume driven for the next four, five years.<\/p>\n

Sachin Ashok Salvi<\/strong><\/p>\n

Okay? Okay, understood. That’s all to me.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. A reminder to all the participants as you may press star and one to ask a question. Next question comes from the line of Tamian Tkerai with hsbc. Please go ahead.<\/p>\n

Damayanti Kerai<\/strong><\/p>\n

Hi, good morning and thank you for the opportunity. I have two broader industry based questions. So first, what is your observation on competition for doctors in some of your key markets in Bangalore? Whether it’s becoming more competitive or it’s not an issue for you. So if you can comment on that part.<\/p>\n

Operator<\/strong><\/p>\n

I think Hyderabad is the most competitive from all the geographies that we are present in. Even in the last one year at least four or five hospitals got commissioned only in hydrothering. We have not seen any doctor significant doctor attrition. We lost one or two doctors but nothing material that we are worried of. We are seeing competition intensifying. In fact. In fact we are also adding more capacity and we are pretty confident we’ll be able to get doctors from competition to be able to run.<\/p>\n

Damayanti Kerai<\/strong><\/p>\n

So according to you, what is health? Sorry, please complete.<\/p>\n

Operator<\/strong><\/p>\n

Likewise in all the other markets, Karnataka, Kerala, we have been seeing good traction from all doctors. So anything, any department that we want to go and be able to build, we’re not seeing any significant resistance from doctors to join.<\/p>\n

Damayanti Kerai<\/strong><\/p>\n

Okay, so According to you, what are the key initiatives or key incentives from Kim’s side? It is retaining the key doctors because what we have seen in across market, whenever new hospitals come up, I guess there are some electrician from the incumbents etc. So what according to you is helping to retain the talent which you have in your hospital?<\/p>\n

Operator<\/strong><\/p>\n

I guess they’re very comfortable in our hospital and they’re happy to continue to work here. They don’t see any infinity IUI that they will get by moving from this hospital.<\/p>\n

Damayanti Kerai<\/strong><\/p>\n

Okay, my second question is actually continuation of earlier discussion on the insurance impanement. So if you can again I think explain, I didn’t get very well. What is the dynamics which has actually changed and that has caused to delay in the impalment? You mentioned the gipsy involvement etc. And then we have been hearing about the common, common impandiment initiatives etc. So it seems like lot of changes or discussions happening on that part. So just want to hear your thoughts or observations there.<\/p>\n

Operator<\/strong><\/p>\n

Yeah, I think gic, they have come up with an initiative, gic where common impediments have to happen and that’s where we lost significant time in trying to understand which is the model to empanel hospitals. So that’s an initiative by all insurance companies and it’s going to continue, it will strengthen moving forward. Because it’s a new initiative this year. There is been some confusion around how things should move forward. And also given we have commissioned so many hospitals in different micro markets in different cities and you know, when we are going and approaching insurance companies for 10 impairments at the same time less we’re talking about renewals at the same time that has kind of led to, you know, delayed response from them also.<\/p>\n

Not that they’re not working towards it, but given that there are so many things that they had to work on from one single company, that’s where we had to, you know, take time and for each hospital to finish first and then go to the other hospitals.<\/p>\n

Damayanti Kerai<\/strong><\/p>\n

Sure. And what’s your view on a common impanelement initiative? Will, will you be considering that or what are your key resistance against that?<\/p>\n

Operator<\/strong><\/p>\n

I think if IRDI decides to do something, we have to only follow the rules that they could increase.<\/p>\n

Damayanti Kerai<\/strong><\/p>\n

Okay. Because some of your larger peers, I think they indicated it’s not legally applicable and there are, I think some concerns on pricing, etc. So that’s why I wanted to hear your view.<\/p>\n

Operator<\/strong><\/p>\n

I don’t, I don’t know, I don’t think it’s appropriate to comment on that. Now right now we’re having. We’re pursuing our empowerments with each insurance company.<\/p>\n

Damayanti Kerai<\/strong><\/p>\n

Okay, thank you. I’ll get back.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. Next question comes from the line of Ankush with Sanctum. Please go ahead.<\/p>\n

Sachin Ashok Salvi<\/strong><\/p>\n

So thanks for the opportunity. If he takes earlier calls, we. It was. It was in the article. It was given that December quarter is the quarter where we are finding that the new units have started. And it’s one of the lowest margin in the December quarter. And there is some regular pickup in margins in the business. So just try to get your sense on that. How do you see such a ramp. Ramp up in the margins now in the upcoming quarters?<\/p>\n

Operator<\/strong><\/p>\n

Like I said, you know we should look at it on a cluster. On cluster basis. It’s difficult to look at it at a company level because there are a lot of new hospitals getting commissioned at different clusters. On a cluster basis every quarter there is margin expansion in almost all the clusters including the mature ones. Even in Andhra we are seeing margin expansion, some margin expansion and good revenue growth.<\/p>\n

Sachin Ashok Salvi<\/strong><\/p>\n

That’s it from my side. Thank you sir.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. A reminder to all the participants that you may press star and one to ask a question. Next question comes from the line of Satyam Kumar with AAA Holding Trust. Please go live.<\/p>\n

Sachin Ashok Salvi<\/strong><\/p>\n

Hi, thanks for the opportunity. Actually I have couple of questions. First question is like regarding the Bengaluru arpa. What I can see is like Bengaluru hospital that combined has reported around 85,000 of RPAP. So like do you see this level sustaining going forward? And also like occupancy. I understand like hospitals have been recently operationalized. So occupancy is that very low,<\/p>\n

Operator<\/strong><\/p>\n

Like<\/p>\n

Sachin Ashok Salvi<\/strong><\/p>\n

Around 20 odd percent. So how do you see this occupancy and<\/p>\n

Operator<\/strong><\/p>\n

RPOC playing around? This is my first question. So RPOB like I said, you know, 85,000 for the full year for quarter. The ALOS has been changing and given it’s a new facility and lot of new departments are getting added, it will take time for it to stabilize the length of stay. For all practical purpose you should assume a 75,000 RPOB and model the ramp up based on that. As time passes, as the hospitals mature, the upwork will obviously expand. And as far as occupancy is concerned. Sorry,<\/p>\n

Rahul Jiwani<\/strong><\/p>\n

Excuse me. Please continue.<\/p>\n

Operator<\/strong><\/p>\n

As far as the occupancy is concerned, there has been a healthy growth from a quarter on quarter basis. We are seeing visibility that the ramp up will be quite healthy even in the coming financial year. We should, towards the end of the year we should hit a 35 40% kind of an occupancy and a full bed capacity.<\/p>\n

Sachin Ashok Salvi<\/strong><\/p>\n

Understood. And like how you are planning to add beds in both the hospitals of Bengaluru like right now the operation but is on the lower side. That’s quite understandable. Like how you increase like at what occupancy level you generally tend to increase the count of operational debt<\/p>\n

Operator<\/strong><\/p>\n

60% on the current occupancy. On the current operational beds we will operationalize the other bits. The operationalizing other beds means just adding more manpower. So based on the need on ground we will decide how to operational because the capex for all of these beds are completed.<\/p>\n

Sachin Ashok Salvi<\/strong><\/p>\n

Understood. And one last question slightly for a longer term. So like. Like a couple of years ago you announced expansion plan. What I understand most of the expansion has already been taken care of. So from here on how do you see expansion going forward for let’s say next three, four years since you are also doing qip so what kind of expansion you are aiming for and also what kind of top line and EBITDA growth from growth post perspective slightly for medium term. What’s your your target issue you’d like to share?<\/p>\n

Operator<\/strong><\/p>\n

I think the expansion will continue to happen. We will keep adding more beds on a year on year basis for the next 12 to 24 months a lot of the consolidation of the current hospitals will happen which will also reduce which will also expand margin for us to strengthen the current hospitals. And by then the debt level also will come down to. In spite of the QIP level come down to us significant low number. We will also use the next 2436 months to get the greenfield projects going. So we obviously have plans to expand in Karnataka, in Kerala, Tamil Nadu.<\/p>\n

We are going to add in hospital and obviously continue to expand in Andhra and talent. So similar phase of expansion will happen. But because these are all greenfield projects they’ll again get bundled up once after three o’. Clock.<\/p>\n

Sachin Ashok Salvi<\/strong><\/p>\n

Any growth perspective in your mind like what kind of top line or bottom line you are eyeing for anything you’d like to share at this moment.<\/p>\n

Operator<\/strong><\/p>\n

Forward looking numbers we are not able to share But I think it should be similar how you know we’ve been able to do in the past.<\/p>\n

Sachin Ashok Salvi<\/strong><\/p>\n

Okay, understood. So thanks.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. Next question comes from the line of Karanpura with Goldman Sachs. Please go ahead.<\/p>\n

Karan Vora<\/strong><\/p>\n

Thank you for the follow up. So just just trying to get a sense on you know what is the key one key challenge for like each of our geographies. If you can highlight it will be helpful. Just one one biggest top of mind Management concern for each of the five states we are present in<\/p>\n

Operator<\/strong><\/p>\n

Right now. The only challenge I see is the insurance environment. You know, whatever we have learned in Kanye Sangalore last week, all new clusters, we’ve not seen it any different from how things are in apn. Development, attracting talent building hospitals ramp up are very similar. The experience has been very similar. Only challenge we faced in this ramp up was the insurance of time.<\/p>\n

Karan Vora<\/strong><\/p>\n

Okay, got it. So basically applicable only to the new hospitals which we are kind of operationalizing, not to the existing ones. No challenges in any of the existing hospitals. Okay. Our second question is with respect to other doctor pay and strategy in existing versus new geographies. Are we a kind of having some different strategies in newer markets like Bangalore or Kerala or Thane versus what we do in Andhra Pradesh Telangana. Are we paying up? Are we like where do we stand in terms of paying to doctors?<\/p>\n

Are we top quartile? Are we like just above average, average? Any. Any color on the strategy and pay arranges will be helpful.<\/p>\n

Operator<\/strong><\/p>\n

It’s the same thing that we are following in APN Telangana. The same model has been extended to Maharashtra and Karnataka and Kerala. We have not changed anything.<\/p>\n

Karan Vora<\/strong><\/p>\n

Okay, got it. And are we like top quartile in terms of pay versus other larger peers? Above average, average, any color there.<\/p>\n

Operator<\/strong><\/p>\n

We pay based on what we believe that the teams can do. Now I don’t know how to classify them under the kind of category that you’ve been asking, but I think yeah, we’ve been paying pretty well. Whatever we think is healthy enough for ramp up of the hospital, that’s how we look at it.<\/p>\n

Karan Vora<\/strong><\/p>\n

Okay, got it, got it. And just a quick bookkeeping one. So Konapur margin hit. Any qualitative number, any. Any quantitative number or range will be helpful in FY27.<\/p>\n

Operator<\/strong><\/p>\n

I think last time when we did the Sunshine movement there was a 15 to 20 crore or a 25 crore kind of a number when Sunshine moved from its old hospital to the new facility. But because this is a much, much larger facility, we should think of it on similar lines a little more.<\/p>\n

Karan Vora<\/strong><\/p>\n

Okay, got it. Helpful. Thank<\/p>\n

Operator<\/strong><\/p>\n

You. Thank you. A reminder to all the participants that you may press star and one to ask a question. Next question comes from the line of Hareet Ahmed with Evan Des. Please go ahead.<\/p>\n

Unidentified Participant<\/strong><\/p>\n

Good morning, Dr. Adnay, can you talk a bit about the acquisition in Palacard? The kind of revenue EBITDA profile there and the potential that we’re seeing and whether we’ll be consolidating this in our pnl?<\/p>\n

Operator<\/strong><\/p>\n

We will Consolidate this in our P and L. It’s just. It’s like how we have in Kullam. It is a 250 bed hospital, sorry 300 bed hospital. The revenue potential would be around 12 to 15 crores per month over a period of time where currently this month, month of May we should be doing around 6 and a half 7 crores with maybe 5% negative EBITDA. So by next month we should break even in that facility or June, July.<\/p>\n

Unidentified Participant<\/strong><\/p>\n

Okay, got it. And following up on your comment on the net debt reduction post the qip. So is there a broad level that you can guide for from the current 3000 odd crore net debt level that we have post the qip and assuming factoring in some of the capex plans that we have for the year and also the ramp up that we’re expecting at some of the currently loss making hospitals some broad level for FY27 end<\/p>\n

Operator<\/strong><\/p>\n

I think maybe to the tune of thousand crores is what we should retire debt and the rest we will use for losses and additional CapEx in the current facilities Capex that they needed to complete in some of the existing facilities that we’ve commissioned.<\/p>\n

Unidentified Participant<\/strong><\/p>\n

Okay. And lastly on the Telangana cluster given such a large contributor to our overall profits and then the Kundapuru expansion being a fairly Large 1 in FY27, should we expect a growth for the cluster overall or will it be in line with our recent trends or will it be a soft year overall for the cluster?<\/p>\n

Operator<\/strong><\/p>\n

For the cluster I think there should be a healthy growth rate. It won’t be soft, maybe around 10 12% EBITDA growth we should look at for the language historically it’s been higher but given Kondapur and Kompali that just got commissioned it should be in that range.<\/p>\n

Unidentified Participant<\/strong><\/p>\n

Okay, thanks for taking my questions.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. A reminder to all the participants that you may press star and one to ask a question. Next question comes from the line of Rahul Giovanni with IFE Capital. Please go ahead.<\/p>\n

Rahul Jiwani<\/strong><\/p>\n

Yeah Sachin, can you please call out the EBITDA loss from the new units for the entire year as well as the base business EBITDA the way you did for fourth quarter.<\/p>\n

Sachin Ashok Salvi<\/strong><\/p>\n

Sure, I’ll do that. So from the matured unit for the entire financial year we did a revenue of 3,335 crore to be exact out of that 3,931 crore of revenue which we have reported the EBITDA which we have done from the matured unit is about 956 crore out of 8. Again 27 crores of EBITDA which we have reported. Reported. So that says for the newer units. So the units which are in operation for less than one year we did in total 597 crore of revenue and EBITDA erosion for the entire year is about 128 crore.<\/p>\n

So that also says that from the matured unit we continue to do about 29% of EBITDA margin on the overall basis which we continue to do for these mature units in the past.<\/p>\n

Rahul Jiwani<\/strong><\/p>\n

Sure. Thanks. And can you also reiterate the commentary in terms of the breakevens for these new units on a monthly basis which you had called out in your previous call. So has Thane already achieved EBITDA breakeven on a monthly basis? And what are your expectations in terms of when do you think both the Bangalore hospitals should be able to achieve breakeven?<\/p>\n

Sachin Ashok Salvi<\/strong><\/p>\n

So at a March exit, I mean. Yeah, please go ahead Dr. Avina if you want to.<\/p>\n

Operator<\/strong><\/p>\n

No. So Rahul, as far as Tane is concerned, March exit number we were EBITDA neutral. April also we were EBITDA neutral. But also we added some doctors now again in the month of May. So there might be some drag there but it’s, it’s going in the right direction. We’re seeing growth on a year on. On a month, on month basis. The only roadblock currently for that growth is the imperilments. Once that is done, I think there will be more traction for growth as far as Bangalore is concerned. Like we said Madhyapuram within 12 months of commissioning.<\/p>\n

We commissioned it in October, 12 months from then we should break. We should. There was one month we were EBITDA positive in Madhyapuram. EBITDA neutral, not positive. But I think before October we should become EBITDA positive. Single digit positive in Mario forum as far as Pest is concerned. Again we’re pretty confident with the trajectory. End of the financial year we should get to a EBITDA positive<\/p>\n

Rahul Jiwani<\/strong><\/p>\n

End of financial year which means March 27th for Electronic City. Sure doctor. And let’s say with. Obviously this year you will have some impact from. But all these other new units should scale up. So this entire EBITDA loss which you had for the year to the tune of 120 crore, kind of a drag from these new units. What kind of an expectation you have in terms of let’s say the combined losses from these new hospitals going into FY27 and 28.<\/p>\n

Operator<\/strong><\/p>\n

It’s difficult to quantify that. Now Raul is just waiting for these impairments to be done and then the ramp ups can Happen faster but obviously it will be less than half. Half the number.<\/p>\n

Rahul Jiwani<\/strong><\/p>\n

Okay, okay. Sure, sure, sure. Okay. I will join by the. Thanks doctor.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. Next question comes from the line of Aditi Chera with Incredible asset management. Please go ahead.<\/p>\n

Sachin Ashok Salvi<\/strong><\/p>\n

Thanks for taking my question. Would like to know the management’s perspective on balancing the current cost of debt and the cost of equity that we’re looking to raise. So how do you view the capital structure and your view on the optimal mix for the capital structure and fundraise?<\/p>\n

Operator<\/strong><\/p>\n

No, I think given the feedback from most of our investors, you know they all believe that a healthy mid debt to EBITDA ratio should be 1 is to 2. So now that it’s slightly higher than 1 is, it’s at 1 3. We wanted to bring it down to that healthy number and that’s the purpose of doing this qip and also it will ease out some cash flow for us when we want to do these new greenfield expansion.<\/p>\n

Sachin Ashok Salvi<\/strong><\/p>\n

Got it sir. Thanks.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. A reminder to all the participants atima press star and one to ask questions. Once again a reminder to all the participants that you may press star and one to ask a question. Ladies and gentlemen, as there are no further questions, we have reached the end of question and answer session and now I’d like to hand the conference over to the management for closing comments.<\/p>\n

Bhaskara Rao Bollineni<\/strong><\/p>\n

So thank you very much for all the relevant questions. And as we already ramped up and given the knowledge that our entire aim is to see that whatever the last five years we have been achieved I keep on telling that in the next few years, next five years also we’ll try to achieve the same growth. That’s why we are trying to do these expansions Greenfield, Brownfield as well as the uapo. The reason is and also we were mentioning all the time that our debt EBITDA should not cross more than one is to two and also the asset ratios and keeping all those things the CAT this quarter and the EPS and all this Norway ROC has come down.<\/p>\n

So we realize we know that this one, this financial year it will cross the whatever expectations of the all these things. That’s why we are raising this funds so that to keep the company healthy and also at the same time we’ll do a steady expansion plans with that. I think whatever is the losses that we have been nearly 120EBITDA eroded and that also comes down in the next year and moving forward I think these will not be much so we can see the company should able to we’re anticipating the company should go on a healthy note in the next three to five years.<\/p>\n

Thank you very much for all the questions. Again,<\/p>\n

Operator<\/strong><\/p>\n

Thank you. On behalf of Kim’s Hospital and iifl Capital. That concludes this conference. Thank you for joining us. You may now disconnect your lines.<\/p>\n","protected":false},"excerpt":{"rendered":"

Note: This is a preliminary transcript and may contain inaccuracies. It will be updated with a final, fully-reviewed version soon. Krishna Institute of Medical Sciences Limited (NSE: KIMS) Q4 2026 Earnings Call dated May. 18, 2026 Corporate Participants: Bhaskara Rao Bollineni \u2014 Founder and Managing Director Sachin Ashok Salvi \u2014 Chief Financial Officer Abhinay Bollineni […]<\/p>\n","protected":false},"author":2377,"featured_media":147581,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[6349],"tags":[10169,9175,9104,9092,14492,10089],"class_list":["post-183277","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-transcripts","tag-earnings","tag-earnings-call","tag-earnings-conference","tag-earnings-transcripts","tag-financial-results","tag-quarterly-earnings"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":141133,"url":"https:\/\/alphastreet.com\/india\/krishna-institute-of-medical-sciences-limited-kims-q3-fy23-earnings-concall-transcript\/","url_meta":{"origin":183277,"position":0},"title":"Krishna Institute of Medical Sciences Limited (KIMS) Q3 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"February 12, 2023","format":false,"excerpt":"Krishna Institute of Medical Sciences Limited (NSE:KIMS) Q3 FY23 Earnings Concall dated Feb. 10, 2023. Corporate Participants: Bhaskar Rao Bollineni\u00a0--\u00a0Founder and Managing Director Abhinay Bollineni\u00a0--\u00a0Executive Director and Chief Executive Officer Vikas Maheshwari\u00a0--\u00a0Chief Financial Officer Analysts: Rahul Jeewani\u00a0--\u00a0IIFL Securities Limited -- Analyst Sagar Shah\u00a0--\u00a0Phillip Capital -- Analyst Piyush\u00a0--\u00a0Individual Investor -- Analyst\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"Earnings Conference Call Transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":137905,"url":"https:\/\/alphastreet.com\/india\/krishna-institute-of-medical-sciences-limited-kims-q2-fy23-earnings-concall-transcript\/","url_meta":{"origin":183277,"position":1},"title":"Krishna Institute of Medical Sciences Limited (KIMS) Q2 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"November 11, 2022","format":false,"excerpt":"Krishna Institute of Medical Sciences Limited (NSE:KIMS) Q2 FY23 Earnings Concall dated Nov. 11, 2022 Corporate Participants: Bhaskar Rao Bollineni -- Founder and Managing Director Vikas Maheshwari -- Chief Financial Officer Abhinay Bollineni -- Executive Director and Chief Executive Officer Analysts: Bhavya Gandhi -- Dalal & Broacha Stock Broking --\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"Earnings Conference Call Transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":125972,"url":"https:\/\/alphastreet.com\/india\/krishna-institute-of-medical-sciences-ltd-kims-q2-fy22-earnings-concall-transcript\/","url_meta":{"origin":183277,"position":2},"title":"Krishna Institute of Medical Sciences Ltd (KIMS) Q2 FY22 Earnings Concall Transcript","author":"Sahil","date":"November 11, 2021","format":false,"excerpt":"Krishna Institute of Medical Sciences Ltd (NSE:KIMS) Q2 FY22 Earnings Concall dated\u00a0 Nov. 11, 2021, Corporate Participants: B. Bhaskar Rao \u2014 Managing Director Abhinay Bollineni \u2014 Director & Chief Executive Officer Vikas Maheshwari \u2014 Chief Financial Officer Analysts: Rahul Jeewani \u2014 IIFL Securities \u2014 Analyst Praveen Sahay \u2014 Edelweiss Financial\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"stock earnings conference call transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/EarningsTranscript.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/EarningsTranscript.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/EarningsTranscript.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":143126,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-of-krishna-institute-of-medical-sciences-limited-for-q3-fy23\/","url_meta":{"origin":183277,"position":3},"title":"Earnings Summary Of Krishna Institute of Medical Sciences Limited For Q3 FY23","author":"Hardik Bhandare","date":"March 1, 2023","format":false,"excerpt":"KIMS is known for providing high-quality healthcare services across various specialties such as cardiology, oncology, orthopedics, neurology, and gastroenterology. The company's hospitals are equipped with state-of-the-art technology and medical equipment, and its medical professionals are highly qualified and experienced. KIMS also offers a range of ancillary services such as diagnostic\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":170676,"url":"https:\/\/alphastreet.com\/india\/kims-q1-fy26-earnings-results\/","url_meta":{"origin":183277,"position":4},"title":"KIMS Q1 FY26 Earnings Results","author":"Chirag Gupta","date":"August 27, 2025","format":false,"excerpt":"Krishna Medical Institution Ltd (KIMS) was Incorporated in the year 1973 and is one of the largest corporate healthcare groups in Andhra Pradesh and Telangana in terms of patients treated and treatments offered. The company offers multidisciplinary healthcare services with primary, secondary, and tertiary care across 2-3 tier cities and\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Krishna Institute of Medical Sciences Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/3-17.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/3-17.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/3-17.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/3-17.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/3-17.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/3-17.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":148006,"url":"https:\/\/alphastreet.com\/india\/krishna-institute-of-medical-sciences-q4fy23-earnings\/","url_meta":{"origin":183277,"position":5},"title":"Krishna Institute of Medical Sciences Q4FY23 Earnings","author":"Karan_Singh","date":"June 1, 2023","format":false,"excerpt":"In terms of the number of patients served and services provided, Krishna Medical Institution Ltd (KIMS), which was founded in 1973, is one of the major corporate healthcare companies in Andhra Pradesh and Telangana. The organisation provides comprehensive healthcare services in 2-3 tier cities with primary, secondary, and tertiary care,\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/science-lab_evotec_-Macrovector.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/science-lab_evotec_-Macrovector.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/science-lab_evotec_-Macrovector.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/science-lab_evotec_-Macrovector.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/183277","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2377"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=183277"}],"version-history":[{"count":1,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/183277\/revisions"}],"predecessor-version":[{"id":183280,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/183277\/revisions\/183280"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/147581"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=183277"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=183277"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=183277"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}